Registration - In-house Corporation

Teva Canada Limited / Teva Canada Limitee / Fabien Paquette, General Manager

Registration Information

In-house Corporation name: Teva Canada Limited / Teva Canada Limitee
Previous in-house corporation names
Responsible Officer Name: Fabien Paquette, General Manager
Responsible Officer Change History
Initial registration start date: 2009-01-13
Registration status: Active
Registration Number: 958840-235321

Associated Communications

Total Number of Communication Reports: 100

Monthly communication reports in the last 6 months: 0

Version 24 of 40 (2019-06-14 to 2019-11-28)

Registration versions:

Version 24 of 40 (2019-06-14 to 2019-11-28)

Lobbying Information

Subject Matters

Budget
Economic Development
Health
Industry
Intellectual Property
International Relations
International Trade
Science and Technology

Subject Matter Details

Policies or Program

An opportunity for a multi-stakeholder approach in developing a solution for childhood diarrhea in low to middle income countries.
Health Canada regarding the development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs), Biologics and Specialty Products.
Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals
Health Canada's consultation on pain medicines.
Innovation, Science and Economic Development Canada. Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
International Trade regarding intellectual property provisions in bilateral and multilateral trade agreements.

Regulation

Innovation, Science and Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.

Communication Techniques

Written communication
Oral communication

Government Institutions

Canadian Heritage (PCH)
Environment and Climate Change Canada (ECCC)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Immigration, Refugees and Citizenship Canada (IRCC)
Immigration and Refugee Board (IRB)
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Senate of Canada

In-house Corporation Details

Description of activities

PHARMACEUTICAL COMPANY Manufacturing and distribution of Generic Prescription Pharmaceuticals Products

Responsible officer name and position during the period of this registration

Christine Poulin, Senior Vice President and General Manager

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
30 Novopharm Court
Toronto, ON M1B 2K9
Canada

Telephone number: 416-940-6767

Parent Company Information

Teva
- 5 Basel St.
  Petach Tikva 49131
  Israel

Subsidiary Beneficiary Information

Teva Canada Limited / Teva Canada Limitee does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Terry Creighton, VP Global Public Policy | No public offices held
Danielle Dupont, Senior Director, Market Access | No public offices held
Benjamin Gray, Vice President & General Counsel | No public offices held
Mathi Mathivanan, Sr Director Regulatory Affairs, Regulatory Affairs | No public offices held
Christine Poulin, Senior VP & GM, Teva Canada Limited | No public offices held
Jason Soler, Director, Market Access | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

No lobbyists added

Teva Canada Limited/Teva Canada Limitee

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Teva Canada Limited/Teva Canada Limitee	2010-11-15	current
Teva Novopharm	2009-01-13	2009-09-03

Teva Canada Limited / Teva Canada Limitee

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Fabien Paquette	2024-07-29	Current
Michael Sine	2022-07-26	2024-07-29
Christine Poulin	2018-04-01	2022-07-26
Douglas Sommerville	2014-01-01	2018-04-01
Barry Fishman	2009-01-13	2014-01-01

Date Modified:: 2025-03-12

Search and menus

Language selection

Registration - In-house Corporation

Teva Canada Limited / Teva Canada Limitee / Fabien Paquette, General Manager

Registration Information

Associated Communications

Version 24 of 40 (2019-06-14 to 2019-11-28)

Version 24 of 40 (2019-06-14 to 2019-11-28)

Subject Matters

Subject Matter Details

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties